{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:07:16Z","timestamp":1783984036450,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01462-6","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:34:38Z","timestamp":1778168078000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseases"],"prefix":"10.1038","volume":"10","author":[{"given":"Sarah","family":"Childs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Cosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Massey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venessa","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"O\u2019Grady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone Kay","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Withers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Callie","family":"Noakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Preisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dion","family":"Forstner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hergen","family":"Buscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"1462_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1462307","volume":"11","author":"C Sainatham","year":"2024","unstructured":"Sainatham, C. et al. The current socioeconomic and regulatory landscape of immune effector cell therapies. Front Med. (Lausanne) 11, 1462307 (2024).","journal-title":"Front Med. (Lausanne)"},{"key":"1462_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1045024","volume":"14","author":"K Zhang","year":"2023","unstructured":"Zhang, K. et al. Bright future or blind alley? CAR-T cell therapy for solid tumors. Front. Immunol. 14, 1045024 (2023).","journal-title":"Front. Immunol."},{"key":"1462_CR3","unstructured":"Biachi de Castria, T. Adoptive cell therapy in solid tumors: how can we mitigate risk and optimize rewards? [Internet]. [cited 2025 Apr 5]. Available from: https:\/\/dailynews.ascopubs.org\/do\/adoptive-cell-therapy-solid-tumors-can-we-mitigate-risk-and-optimize-rewards. 2024."},{"key":"1462_CR4","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.3390\/ijms25084170","volume":"25","author":"J Rojas-Quintero","year":"2024","unstructured":"Rojas-Quintero, J. et al. CAR T cells in solid tumors: overcoming obstacles. Int. J. Mol. Sci. 25, 4170 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1462_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej, K. M. et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol. Cancer 22, 20 (2023).","journal-title":"Mol. Cancer"},{"key":"1462_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"1462_CR7","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/s41375-025-02532-7","volume":"39","author":"BD Shah","year":"2025","unstructured":"Shah, B. D. et al. Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia 39, 1058\u20131068 (2025).","journal-title":"Leukemia"},{"key":"1462_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.46989\/001c.115793","volume":"6","author":"K Gatwood","year":"2024","unstructured":"Gatwood, K. et al. Outpatient CAR T-cell therapy as standard of care: current perspectives and considerations. Clin. Hematol. Int. 6, 11\u201320 (2024).","journal-title":"Clin. Hematol. Int."},{"key":"1462_CR9","unstructured":"PackGene Biotech. Advances in cell and gene therapy and the evolving AAV landscape in 2025 H1 [Internet]. Houston (TX): PackGene Biotech; 2025 Apr 9 [cited 2025 Sept 25]. Available from: https:\/\/www.packgene.com\/learning-center\/advances-in-cell-and-gene-therapy-and-the-evolving-aav-landscape-in-2025-h1\/"},{"key":"1462_CR10","first-page":"96","volume":"52","author":"LT Tony","year":"2025","unstructured":"Tony, L. T., Stabile, A., Schauer, M. P., Hudecek, M. & Weber, J. CAR-T cell therapy for solid tumors. Transfus. Med Hemother 52, 96\u2013108 (2025).","journal-title":"Transfus. Med Hemother"},{"key":"1462_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1352805","volume":"15","author":"V Albarr\u00e1n","year":"2024","unstructured":"Albarr\u00e1n, V. et al. Adoptive T cell therapy for solid tumors: current landscape and future challenges. Front Immunol. 15, 1352805 (2024).","journal-title":"Front Immunol."},{"key":"1462_CR12","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos, D. et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N. Engl. J. Med. 385, 567\u2013569 (2021).","journal-title":"N. Engl. J. Med"},{"key":"1462_CR13","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","volume":"24","author":"JB Chung","year":"2024","unstructured":"Chung, J. B., Brudno, J. N., Borie, D. & Kochenderfer, J. N. Chimeric antigen receptor T cell therapy for autoimmune disease. Nat. Rev. Immunol. 24, 830\u2013845 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"1462_CR14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller, F. et al. CD19 CAR T-cell therapy in autoimmune disease: a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med"},{"key":"1462_CR15","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/jimmun\/vkaf008","volume":"214","author":"D Suan","year":"2025","unstructured":"Suan, D., Moore, J. & Goodnow, C. C. Can autoimmune disease be cured by deep CD19+ cell depletion? J. Immunol. 214, 1075\u20131092 (2025).","journal-title":"J. Immunol."},{"key":"1462_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1616231","volume":"16","author":"Y Chen","year":"2025","unstructured":"Chen, Y. et al. Global clinical trials on stem cell therapy for autoimmune diseases: trends and future directions. Front Immunol. 16, 1616231 (2025).","journal-title":"Front Immunol."},{"key":"1462_CR17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/d41573-022-00095-1","volume":"21","author":"AR Saez-Iba\u00f1ez","year":"2022","unstructured":"Saez-Iba\u00f1ez, A. R. et al. Landscape of cancer cell therapies: trends and real-world data. Nat. Rev. Drug Discov. 21, 631\u2013632 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1462_CR18","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3390\/cancers15041003","volume":"15","author":"V Wang","year":"2023","unstructured":"Wang, V., Gauthier, M., Decot, V., Reppel, L. & Bensoussan, D. Systematic review on CAR-T cell clinical trials up to 2022: academic center input. Cancers (Basel) 15, 1003 (2023).","journal-title":"Cancers (Basel)"},{"key":"1462_CR19","unstructured":"International Agency for Research on Cancer. Cancer Today [Internet]. Lyon (FR): World Health Organization; 2024 Feb 8 [cited 2025 Sep 12]. Data version: GLOBOCAN 2022 (version 1.1). Available from: https:\/\/gco.iarc.who.int."},{"key":"1462_CR20","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41587-025-02691-z","volume":"43","author":"A Mullard","year":"2025","unstructured":"Mullard, A. Brazil\u2019s low-cost CAR-Ts take on Global South. Nat. Biotechnol. 43, 657 (2025).","journal-title":"Nat. Biotechnol."},{"key":"1462_CR21","volume":"21","author":"G Dagar","year":"2023","unstructured":"Dagar, G. et al. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. J. Transl. Med. 21, 504 (2023).","journal-title":"J. Transl. Med"},{"key":"1462_CR22","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jconrel.2024.02.033","volume":"368","author":"T Zhang","year":"2024","unstructured":"Zhang, T. et al. Adoptive cell therapy for solid tumors beyond CAR-T: current challenges and emerging therapeutic advances. J. Control Release 368, 372\u2013396 (2024).","journal-title":"J. Control Release"},{"key":"1462_CR23","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso, B. D. et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor (CAR) T-cell therapy: ASCO guideline. J. Clin. Oncol. 39, 3978\u20133992 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1462_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114075","volume":"205","author":"A G\u00e9raud","year":"2024","unstructured":"G\u00e9raud, A. et al. Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies: a comprehensive review. Eur. J. Cancer 205, 114075 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1462_CR25","first-page":"438.e1","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines, M. R. et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. J. Transpl. Cell Ther. 29, 438.e1\u2013438.e16 (2023).","journal-title":"J. Transpl. Cell Ther."},{"key":"1462_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht, C. T. et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353, 179\u2013184 (2016).","journal-title":"Science"},{"key":"1462_CR27","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen, O. et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat. Med. 27, 2099\u20132103 (2021).","journal-title":"Nat. Med"},{"key":"1462_CR28","first-page":"e309","volume":"7","author":"M Hagen","year":"2025","unstructured":"Hagen, M. et al. Local immune effector cell-associated toxicity syndrome in patients with autoimmune disease receiving CD19-targeting CAR T-cell therapy. Lancet Rheumatol. 7, e309\u2013e316 (2025).","journal-title":"Lancet Rheumatol."},{"key":"1462_CR29","first-page":"255","volume":"29","author":"T Kourelis","year":"2023","unstructured":"Kourelis, T. et al. Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: a multi-institution experience. Transpl. Cell Ther. 29, 255\u2013258 (2023).","journal-title":"Transpl. Cell Ther."},{"key":"1462_CR30","first-page":"2452","volume":"108","author":"EC Ayers","year":"2023","unstructured":"Ayers, E. C. et al. Inferior outcomes of EU versus US patients treated with CD19 CAR T. Haematologica 108, 2452\u20132461 (2023).","journal-title":"Haematologica"},{"key":"1462_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1501365","volume":"15","author":"S Argueta","year":"2024","unstructured":"Argueta, S. et al. In vivo programmed myeloid cells expressing novel chimeric antigen receptors show potent anti-tumor activity in preclinical solid tumor models. Front Immunol. 15, 1501365 (2024).","journal-title":"Front Immunol."},{"key":"1462_CR32","unstructured":"Peter MacCallum Cancer Centre. CAR T-cell therapy: a guide for patients, carers and families [Internet]. Melbourne: Peter MacCallum Cancer Centre; [cited 2025 May 24]. Available from: https:\/\/www.petermac.org\/patients-and-carers\/information-and-resources\/car-t-cell-therapy-a-guide-for-patients-carers-and-families"},{"key":"1462_CR33","unstructured":"IQVIA Institute for Human Data Science. Achieving CAR T-cell therapy health system readiness: an assessment of barriers and opportunities. Available from: https:\/\/www.iqviainstitute.org. March 2025."},{"key":"1462_CR34","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41409-021-01463-y","volume":"57","author":"E Trias","year":"2022","unstructured":"Trias, E., Juan, M., Urbano-Ispizua, A. & Calvo, G. The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001. Bone Marrow Transpl. 57, 156\u2013159 (2022).","journal-title":"Bone Marrow Transpl."},{"key":"1462_CR35","unstructured":"GoCART Coalition. UNITC: The French Consortium advancing Cancer Cell and Gene Therapy [Internet]. 2025 Jan 15 [cited 2025 Sept 12]. Available from: https:\/\/thegocartcoalition.com\/unitc-the-french-consortium-advancing-cancer-cell-and-gene-therapy\/"},{"key":"1462_CR36","unstructured":"American Society of Hematology. CAR-T Toxicities Consortium [Internet]. [cited 2025 Sep 12]. Available from: https:\/\/www.hematology.org\/research\/car-t-toxicities-consortium"},{"key":"1462_CR37","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/s41409-025-02637-8","volume":"60","author":"C Marton","year":"2025","unstructured":"Marton, C. et al. Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium. Bone Marrow Transpl. 60, 1209\u20131217 (2025).","journal-title":"Bone Marrow Transpl."},{"key":"1462_CR38","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","volume":"45","author":"L Short","year":"2024","unstructured":"Short, L., Holt, R. A., Cullis, P. R. & Evgin, L. Direct in vivo CAR T cell engineering. Trends Pharm. Sci. 45, 406\u2013418 (2024).","journal-title":"Trends Pharm. Sci."},{"key":"1462_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217881","volume":"630","author":"Q Wen","year":"2025","unstructured":"Wen, Q. et al. Artificial intelligence in predicting efficacy and toxicity of immunotherapy: Applications, challenges, and future directions. Cancer Lett. 630, 217881 (2025).","journal-title":"Cancer Lett."},{"key":"1462_CR40","unstructured":"FACT Standards for Immune Effector Cells in the Community Clinical Setting, First Edition [digital version]. Bethesda (MD): Foundation for the Accreditation of Cellular Therapy (FACT). Available from: https:\/\/www.factglobal.org\/education-and-resources\/general\/press-releases\/20255-fact-community-iec-standards; 2025."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01462-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01462-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01462-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:59:37Z","timestamp":1783983577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01462-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1462"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01462-6","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Several authors are investigators on cellular therapy clinical trials and receive institutional funding to support the conduct of these trials. These funds are provided to their institutions and not directly to the authors. No personal financial interests are declared in relation to the subject matter of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"280"}}